Aidan Power

Dr. Power brings over 25 years of drug development experience to Alzheon. From June 2015 through December 2020 he served as the Vice President of Program and Portfolio. Previously, Dr. Power was Vice President and Head of PharmaTherapeutics Precision Medicine at Pfizer Global Research and Development in New London, CT, where he led a diverse group providing genomics, genetics, and imaging expertise to projects across Cardiovascular, Neurosciences, and Pain therapeutic areas, supporting novel target identification, biomarker development and precision medicine strategies for early-stage clinical programs. Dr. Power led major external partnerships at Pfizer including the Yale/Pfizer Bioimaging Alliance and Pfizer/NIH/NCATS’ New Therapeutic Uses Initiative. His group developed and delivered collaborations with major academic institutions including the University of Cambridge, the Karolinska Institutet, University College London, and Washington University in St. Louis. During more than 20 years at Pfizer in both the UK and the US, Dr. Power developed and led the implementation of strategic organizational changes for technology groups.

Dr. Power’s groups have been at the forefront of pharmacogenomics and personalized medicine, establishing the first large-scale automated biobank in the pharmaceutical industry and developing integrated DNA sample collection from clinical trials, and conducting large-scale pharmacogenetics studies. He was a founding board member of the International Serious Adverse Event Consortium and served on the board of the Personalized Medicine Coalition. Earlier in his career, Dr. Power was responsible for running Phase 3 studies in Europe for the Geodon® schizophrenia program.

Dr. Power earned his medical degree MB, BCh, BAO from University College Cork, Ireland, and an MSc in the History of Science and Medicine from University College London. He is a member of the Royal College of Psychiatrists.